Today it was reported that a Director at Genomic Health (NASDAQ: GHDX), Fred E. Cohen, exercised options to sell 8,250 GHDX shares at $34.44 a share, for a total transaction value of $507.4K.
Following Fred E. Cohen’s last GHDX Sell transaction on August 09, 2018, the stock climbed by 7.4%.
See today’s analyst top recommended stocks >>
Based on Genomic Health’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $95.62 million and quarterly net profit of $8.32 million. In comparison, last year the company earned revenue of $85.49 million and had a GAAP net loss of $2.74 million. GHDX’s market cap is $2.24B and the company has a P/E ratio of 567.73. Currently, Genomic Health has an average volume of 337.5K.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $51.08, reflecting a -20.1% downside.
The insider sentiment on Genomic Health has been positive according to 58 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
